About Crescendo Bioscience
Crescendo Bioscience is a Healthcare company based in San Francisco (United States) founded in 2002, and was acquired by Myriad Genetics in February 2014. Molecular tests for autoimmune and inflammatory diseases are provided. Crescendo Bioscience has raised $122.05 million across 4 funding rounds from investors including Kleiner Perkins, Myriad Genetics and HHS. The company has 128 employees. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its legal entity is Crescendo Bioscience LLC. Its competitors include Guardant Health, Natera and Foundation Medicine; 3 of its 3 listed competitors have raised funding.
Company details
Crescendo Bioscience was founded in 2002 in San Francisco, United States, as a CLIA-certified laboratory in the biotechnology sector. Molecular diagnostic tests are offered to support management of patients with autoimmune and inflammatory conditions. The Vectra DA assay, which evaluates 12 biomarkers for rheumatoid arthritis, is utilized to measure disease activity and predict therapy responses. Acquisition by Myriad Genetics occurred in February 2014 for 270 million.
- Headquarters San Francisco, United States
- Employees 128
- Stage Acquired
- SectorsHealthcare
- Website crescendobio.com
- Social LinkedIn X
- Acquired by Myriad Genetics (Feb 2014)
- Legal Name Crescendo Bioscience Llc
- Total Equity Funding$122.05M (USD)
in 4 rounds
- Latest Funding Round$28.45M (USD), Series D
Dec 2012
- InvestorsKleiner Perkins
& 6 more
- Employee Count128
- Acquired byMyriad Genetics
(Feb 2014)
Funding Insights of Crescendo Bioscience
Crescendo Bioscience has successfully raised a total of $122.05M across 4 strategic funding rounds. The most recent funding activity was a Series D round of $28.45 million completed in December 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $122.05M
- Total Rounds 4
- Last Round Series D — $28.45M
- First Round $147,000
(Oct 2008)
- Investors Count 6
All 4 funding rounds of Crescendo Bioscience with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2012 | $28.45M | Series D | – | Skyline Ventures | |
| Jun 2011 | $56M | Series C | – | Calibrium, Mohr Davidow Ventures | – |
| Jul 2010 | $37.6M | Series C | – | – | – |
| Oct 2008 | $147,000 | Grant | – | – |
7 investors in total: 7 institutional.
Investors in Crescendo Bioscience
Crescendo Bioscience has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Kleiner Perkins, Myriad Genetics and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
US life sciences companies are invested in by Skyline Ventures. | skylineventures.com | Palo Alto, United States | ||
Venture capital firm investing in early and growth stage companies | 1953 | safeguard.com | Radnor, United States | |
Venture capital investments are managed in technology and healthcare sectors by this firm. | mdv.com | |||
Venture capital firm investing in early-stage tech startups | 1972 | kleinerperkins.com | Menlo Park, United States | |
Private investment services are offered by Calibrium for clients. | clbrm.com | Zürich, Switzerland | ||
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Molecular diagnostics and personalized medicine for cancer are developed. | 1991 | myriad.com | United States |
Investor details for Crescendo Bioscience
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Crescendo Bioscience
4 dated milestones of Crescendo Bioscience across 12 years, from founding to its latest funding, stage changes and deals.
- Founded Crescendo Bioscience is founded.
- Funding First funding round of $147K.
- Funding Latest funding round, Series D, of $28.5M.
- Exit Acquired by Myriad Genetics.
Competitors of Crescendo Bioscience
Crescendo Bioscience has 3 listed competitors in our database, 3 of them funded. They include Guardant Health, Natera and Foundation Medicine.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| guardanthealth.com | 2012 | Redwood, United States | $557.5M | 1,351 | Digital sequencing technology for cancer detection is developed. | |
| natera.com | 2004 | Redwood, United States | $152.1M | 3,293 | Developer of cell-free DNA testing for oncology, women’s health, and organ health | |
| foundationmedicine.com | 2010 | Cambridge, United States | $96.5M | 1,707 | Genomics-based diagnostic tests for cancer are provided. |
Detailed competitors of Crescendo Bioscience
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Crescendo Bioscience
Websites that share an audience with Crescendo Bioscience (crescendobio.com).
Websites whose visitors overlap most with Crescendo Bioscience. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| crescendobiologics.com | 100% | #13,705,548 | View details | ||
| genomichealth.com | 92% | 1.9K | #5,157,031 | View details | |
| altorbioscience.com | 76% | View details | |||
| veracyte.com | 75% | 53.7K | #739,418 | View details | |
| biosciencelabs.com | 75% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 12 similar websites and full traffic analytics for Crescendo Bioscience
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 12 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Crescendo Bioscience (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Crescendo Bioscience
Crescendo Bioscience was founded in 2002 and raised its 1st funding round 6 years after it was founded.
Crescendo Bioscience is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Crescendo Bioscience is a funded company, having raised a total of $122.05M across 4 funding rounds to date. The company's 1st funding round was a Grant of $147K, raised on Oct 2008.
Crescendo Bioscience has 128 employees.
Crescendo Bioscience was founded in 2002 in San Francisco, United States, as a CLIA-certified laboratory in the biotechnology sector. Molecular diagnostic tests are offered to support management of patients with autoimmune and inflammatory conditions. The Vectra DA assay, which evaluates 12 biomarkers for rheumatoid arthritis, is utilized to measure disease activity and predict therapy responses. Acquisition by Myriad Genetics occurred in February 2014 for 270 million.
Crescendo Bioscience's top competitors include Guardant Health, Foundation Medicine and Natera.
Crescendo Bioscience has 7 investors. Key investors include Kleiner Perkins, Myriad Genetics, HHS, Safeguard Scientifics, and Skyline Ventures.
Crescendo Bioscience operates through Crescendo Bioscience Llc.
Yes. Crescendo Bioscience was acquired by Myriad Genetics in February 2014.